Laurus Labs

Manufacturing Facilities

Manufacturing Facilities and Approvals

We currently operate three manufacturing facilities in Vishakhapatnam, Andhra Pradesh. Two facilities manufacture APIs and ingredients, while our third facility is for the manufacturing of APIs & FDFs. WHO and USFDA have successfully conducted their last inspection for two of our facilities in Vishakapatnam in April 2015 and USFDA successfully conducted their last inspection at our Kilo Lab at Hyderabad in June 2016.
Our manufacturing facilities have received one or more approvals from USFDA, KFDA, PMDA, BfArM and WHO. Laurus Labs also operates a Kilo Lab at the R&D center in Hyderabad and currently in the process of setting up two additional manufacturing facilities in Vishakapatnam.

Unit Location Description Approvals
kilo lab Plot no. DS1 and DS2, IKP Knowledge Park, Turkapally,
Shameerpet, Ranga Reddy District, Hyderabad 500078, Telangana, India
43 reactors and a capacity of 4.6 KL. US FDA, KFDA and PMDA.
1. Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing. 300 reactors with a total capacity of 1,140 KL. US FDA, WHO-Geneva, NIP Hungary, KFDA and PMDA.
The latest successful audit by US FDA and WHO-Geneva was in April 2015.
2. Plot No. 19, 20, 21, APSEZ, Achutapuram, Visakhapatnam 531 011, Andhra Pradesh, India FDF and API manufacturing facility.
Plant with a capacity of 1 billion tablets/year.
API block with 12 reactors and total capacity of 84 KL.
BfArM – Germany. The latest successful audit was in December 2015.
3. Plot No. 18, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing.

80 reactors installed with a total capacity of 605 KL which is being expanded to 110 reactors with a total capacity of 729 KL and the expansion is expected to be completed in the quarter ending December 2016.
US FDA, WHO-Geneva, and EU.
The latest successful audit by US FDA and WHO-Geneva was in April 2015.

 

New manufacturing facilities under construction:

Unit Location Description Status
4. Plot No 25, 25A to 25K, APSEZ – Denotified Area, Alalamkoduru Village, Rambilli (M), Visakhapatnam, Andhra Pradesh Nutraceuticals and APIs manufacturing facility. Construction to commence during the financial year 2017.
5. SEZ at Plot No 102 and 103, Lemarthi Village, Parwada (M), Visakhapatnam 531 021, Andhra Pradesh API manufacturing facility with planned capacity of 48 reactors with a total capacity of 138 KL dedicated to potent intermediates and APIs. Expected to commence operations by December 31, 2016.
Top